Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Molecular predictors of survival in patients with myeloproliferative neoplasm-blast Phase (MPN-BP) treated with venetoclax and decitabine

View Full Paper
Ask AI
Bookmark
Share

Authors

FMFrancesco MannelliSSStefano SodduMVMarco Vignetti

Discussion

Loading...

Member takes

Overview

Phase 2 trial assesses venetoclax and decitabine impact on overall survival in MPN-BP, suggesting a focus on genetic factors.

Key Points

  • Define a prognostic risk profile for survival in patients with MPN-BP treated with venetoclax and decitabine.
  • Phase 2 trial enrolling 101 patients with MPN-BP.
  • DNA from purified blasts analyzed for mutations using PCR assays and NGS sequencing.
  • Karyotype abnormalities classified according to established guidelines.
  • Karyotype and molecular data available for 80 patients, with 90% having driver mutations.
  • A 3-gene risk score including SRSF2, U2AF1, and TP53 accurately identified survival categories.
  • Significant differences in overall survival were observed across risk categories.

Cite This Study

Mannelli et al. (2025) studied this question.

synapsesocial.com/papers/693624d74fa91c937236d122https://doi.org/10.1182/blood-2025-3751
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Refined genetic risk model with complex karyotype predicts outcomes of newly diagnosed acute myeloid leukemia treated with decitabine plus venetoclax2025
  2. 2Genetic risk model to predict outcomes for AML treated with HMA and venetoclax2025
  3. 3Venetoclax and decitabine in myeloproliferative neoplasm-blast Phase (MPN-BP): Results of enable, a gimema and airc-mynerva multicenter, Phase 2 trial2025 · 5 citations
  4. 4Genetic risk stratification in adults with AML receiving venetoclax-based intensive therapy: A real-world study2025
  5. 5Outcomes of blast-phase MPN and <i>JAK2</i>, <i>MPL</i>, and <i>CALR</i>mutated de novo AML: A propensity score-adjusted cohort study.2024